drugset / Trial / NCT03971734

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734

Non-randomizedSequentialOpen-labelTreatment

Summary

enroll patients with histologically confirmed high-grade gliomas to evaluate the ability of regadenoson to transiently disrupt a relatively intact blood-brain barrier (BBB). determine the best dose of regadenoson to disrupt the BBB and allow for enhanced penetration of gadolinium during MRI.

Timeline

Start
2019-12-06
Primary completion
2022-04-30
Completion
2023-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Regadenoson Diagnostic / imaging agent 0.05 mg
Subject Regadenoson Diagnostic / imaging agent 0.1 mg
Subject Regadenoson Diagnostic / imaging agent 0.2 mg
Subject Regadenoson Diagnostic / imaging agent 0.4 mg
Subject Regadenoson Diagnostic / imaging agent 0.7 mg
Subject Regadenoson Diagnostic / imaging agent 1 mg
Subject Regadenoson Diagnostic / imaging agent 1.4 mg